NYSE:VIT - VanceInfo Technologies Stock Price, Price Target & More

$0.42 +0.42 (+Infinity)
(As of 04/23/2018 04:00 PM ET)
Previous Close$0.42
Today's Range$0.4150 - $0.4250
52-Week RangeN/A
Volume81,901 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About VanceInfo Technologies (NYSE:VIT)

VanceInfo Technologies logoVanceInfo Technologies Inc. (VanceInfo) is a holding company. VanceInfo is an information technology (IT) service provider and is offshore software development company. VanceInfo is principally engaged in the provision of IT services, which include quality assurance testing, application development and maintenances (ADMs), research and development (R&D), globalization and localization, and enterprise solutions in the People's Republic of China. It categorizes its services into three sets: R&D Outsourcing Services, IT Services, and other solutions and services. In February 2012, it acquired 100% interest in Beijing Sunwin Technology Co., Ltd., and 50% interest in Beijing Yunxiang Weiye Information Technology Co., Ltd. In October 2011, the Company acquired the assets and the professional team of the United Sates-based IT services company. On August 1, 2011, it acquired 100% interest in Beijing Data Pioneer Information Technology Co., Ltd.

Receive VIT News and Ratings via Email

Sign-up to receive the latest news and ratings for VIT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNYSE:VIT
CUSIPN/A
Phone+86-10-82825266

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

How to Become a New Pot Stock Millionaire

VanceInfo Technologies (NYSE:VIT) Frequently Asked Questions

What is VanceInfo Technologies' stock symbol?

VanceInfo Technologies trades on the New York Stock Exchange (NYSE) under the ticker symbol "VIT."

Has VanceInfo Technologies been receiving favorable news coverage?

Press coverage about VIT stock has been trending somewhat positive on Monday, Accern Sentiment reports. Accern scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. VanceInfo Technologies earned a daily sentiment score of 0.12 on Accern's scale. They also assigned news headlines about the technology company an impact score of 45.99 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of VanceInfo Technologies?

Shares of VIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is VanceInfo Technologies' stock price today?

One share of VIT stock can currently be purchased for approximately $0.42.

How can I contact VanceInfo Technologies?

VanceInfo Technologies' mailing address is 3F, Building 8, Zhongguancun Software Park,Haidian Dist., BEIJING, BEJ 100094, China. The technology company can be reached via phone at +86-10-82825266.


MarketBeat Community Rating for VanceInfo Technologies (VIT)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  64 (Vote Outperform)
Underperform Votes:  57 (Vote Underperform)
Total Votes:  121
MarketBeat's community ratings are surveys of what our community members think about VanceInfo Technologies and other stocks. Vote "Outperform" if you believe VIT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

VanceInfo Technologies (NYSE:VIT) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 4/23/2016 forward)

Earnings

VanceInfo Technologies (NYSE:VIT) Earnings History and Estimates Chart

Earnings by Quarter for VanceInfo Technologies (NYSE:VIT)

VanceInfo Technologies (NYSE VIT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/10/2012$0.20$0.19ViewN/AView Earnings Details
5/15/2012$0.15$0.16ViewN/AView Earnings Details
2/28/2012$0.20$0.20ViewN/AView Earnings Details
11/15/2011$0.20$0.14ViewN/AView Earnings Details
8/16/2011$0.23$0.21ViewN/AView Earnings Details
5/16/2011$0.20$0.20ViewN/AView Earnings Details
2/28/2011$0.21$0.22ViewN/AView Earnings Details
11/17/2010Q3 2010$0.17$0.19ViewN/AView Earnings Details
8/17/2010Q2 2010$0.17$0.18ViewN/AView Earnings Details
5/13/2010Q1 2010$0.14$0.16ViewN/AView Earnings Details
2/25/2010Q4 2009$0.14$0.17ViewN/AView Earnings Details
11/17/2009Q3 2009$0.14$0.16ViewN/AView Earnings Details
8/14/2009Q2 2009$0.12$0.13ViewN/AView Earnings Details
5/13/2009Q1 2009$0.10$0.10ViewN/AView Earnings Details
2/24/2009Q4 2008$0.11$0.13ViewN/AView Earnings Details
11/17/2008Q3 2008$0.10$0.12ViewN/AView Earnings Details
8/14/2008Q2 2008$0.09$0.09ViewN/AView Earnings Details
5/9/2008Q1 2008$0.06$0.08ViewN/AView Earnings Details
2/27/2008Q4 2007$0.08$0.07ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

VanceInfo Technologies (NYSE:VIT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

VanceInfo Technologies (NYSE VIT) Insider Trading and Institutional Ownership History

Insider Trading History for VanceInfo Technologies (NYSE:VIT)

VanceInfo Technologies (NYSE VIT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

VanceInfo Technologies (NYSE VIT) News Headlines

Source:
DateHeadline
How Branding Will Decide Winners and Losers in the Upcoming Legal Cannabinoid MarketplaceHow Branding Will Decide Winners and Losers in the Upcoming Legal Cannabinoid Marketplace
www.baystreet.ca - March 12 at 4:25 PM
Chemiluminescence Immunoassay (CLIA) Analyzers Market: Improving Sensitivity & Growing Test Offerings to Fuel Market Growth, Says TMRChemiluminescence Immunoassay (CLIA) Analyzers Market: Improving Sensitivity & Growing Test Offerings to Fuel Market Growth, Says TMR
www.prnewswire.com - March 8 at 4:13 PM
Powerful and Safe Supplement for Brain Health Now Available as Food IngredientPowerful and Safe Supplement for Brain Health Now Available as Food Ingredient
www.bizjournals.com - March 8 at 4:13 PM
Global oxygen scavenger market growth is expected to be driven by demand from food & beverages industryGlobal oxygen scavenger market growth is expected to be driven by demand from food & beverages industry
www.marketwatch.com - February 9 at 6:11 PM
Phivida Begins Mass Production for California Retail MarketPhivida Begins Mass Production for California Retail Market
www.bizjournals.com - February 1 at 5:05 PM
Hydroxycut® Launches New Digital Tools to Help Americans Reach Their Weight Loss Goals in 2018Hydroxycut® Launches New Digital Tools to Help Americans Reach Their Weight Loss Goals in 2018
finance.yahoo.com - December 29 at 5:43 PM
Ultragenyx and Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion for the Treatment of X-Linked Hypophosphatemia in ChildrenUltragenyx and Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion for the Treatment of X-Linked Hypophosphatemia in Children
finance.yahoo.com - December 15 at 9:15 AM
Ultragenyx and Kyowa Kirin Announce Positive 48-Week Data from Adult Phase 3 Study of Burosumab (KRN23) in X-Linked HypophosphatemiaUltragenyx and Kyowa Kirin Announce Positive 48-Week Data from Adult Phase 3 Study of Burosumab (KRN23) in X-Linked Hypophosphatemia
finance.yahoo.com - December 4 at 8:53 AM
UGG Maker Deckers Urges Support for DirectorsUGG Maker Deckers Urges Support for Directors
finance.yahoo.com - November 19 at 10:19 AM
Vertical Farming developing sustenance in vertical stacked layers, set to witness a CAGR of 24.9% during 2017-2023Vertical Farming developing sustenance in vertical stacked layers, set to witness a CAGR of 24.9% during 2017-2023
globenewswire.com - November 7 at 11:18 PM
Rockwell Medical Technologies (RMTI) Says FDA Requested Extra Time to Review Calcitriol Post-Approval Drug Manufacturing SubmissionRockwell Medical Technologies (RMTI) Says FDA Requested Extra Time to Review Calcitriol Post-Approval Drug Manufacturing Submission
www.streetinsider.com - October 25 at 9:10 PM
Pure Encapsulations® Expands Successful PureGenomics™ Platform to CanadaPure Encapsulations® Expands Successful PureGenomics™ Platform to Canada
www.bizjournals.com - October 25 at 4:01 PM
GMO Crops and Seeds Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2022GMO Crops and Seeds Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2022
finance.yahoo.com - October 18 at 4:07 PM
Jan Marini Skin Research Promotes John Connors to CEO & PresidentJan Marini Skin Research Promotes John Connors to CEO & President
globenewswire.com - July 12 at 5:29 PM

SEC Filings

VanceInfo Technologies (NYSE:VIT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

VanceInfo Technologies (NYSE:VIT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

VanceInfo Technologies (NYSE VIT) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.